Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature.

Improved surgical techniques and superior posttransplant care have increased graft survival after solid organ transplantation, and complications of lifelong immunosuppression are increasingly prevalent in clinical practice. The excess relative risk of melanoma attributable to transplantation is between 2 and 12 times that of the general population,1 and given the high tumor burden, this has important implications for the surveillance and management of organ transplant recipients (OTRs). Several risk factors for melanoma are known, including immunosuppression, the presence of atypical nevi, light skin phototype, ultraviolet light exposure, and a family or personal history of skin cancer.1, 2 Here we report a case of cutaneous melanoma arising posttransplant, highlighting the substantial morbidity and mortality of this disease in OTR. In view of the increased risk of melanoma and high potential for metastasis, dermatologists should monitor OTRs closely and institute multidisciplinary care without delay.